<DOC>
	<DOCNO>NCT01280981</DOCNO>
	<brief_summary>This multicenter , open-label extension study subject complete either 2 pivotal efficacy study ( NCT00401193 NCT00386308 ) . The study consist treatment phase 9 menstrual period assess safety tranexamic acid oral dose 1.3 g administer 3 time per day 5 day ( maximum 15 dos ) menstruation . After last treatment period , follow-up phone call occur approximately 30 day ( range 25 35 day ) last dose study drug .</brief_summary>
	<brief_title>A Study Tranexamic Acid ( XP12B ) Women With Heavy Menstrual Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>The study enrol subject complete doubleblind therapy either XP12BMR301 XP12BMR303 study , include schedule evaluation , major protocol violation study event , opinion investigator , would preclude subject 's entry openlabel safety study . A negative urine pregnancy test require immediately entry study . Women must surgically sterile , childbearing potential , must monogamous relationship sterile partner partner sex . Women must use acceptable barrier contraception method spermicide duration study must use copper intrauterine device ( IUD ) . In opinion investigator , subject must able understand study , cooperate study procedure , able return study site visit within require visit window deem likely complete study . Subject provide voluntary , write consent participate study sign date institutional review board ( IRB ) approve informed consent procedure perform study drug dispense . History presence clinically significant hepatic renal disease medical disease might confound study detrimental subject ( e.g. , clinically significant cardiac arrhythmia , uncontrolled diabetes uncontrolled hypertension ) determine investigator . Normal gynecological examination breast examination . Clinically significant abnormality screen physical examination might confound study detrimental subject assess investigator . Abnormal clinically significant electrocardiogram ( ECG ) determine centralized cardiologist , laboratory test suggestive potential pituitaryprolactin stimulate tumor ( prolactin &gt; =30 µg/L ) , thrombocytopenia ( platelet count &lt; 100,000/mm3 ) , uncontrolled hypothyroidism ( TSH &gt; =10 mU/L ) severe anemia ( hemoglobin &lt; 8 g/dL ] ) . Anovulatory dysfunctional uterine bleeding , metrorrhagia ( irregular frequent noncyclic flow ) , menometrorrhagia ( irregular frequent excessive noncyclic flow ) polymenorrhea ( frequent flow , cycle less 21 day ) . History presence endometrial polyp , endometrial hyperplasia , endometrial carcinoma cervical carcinoma ( include cervical carcinoma situ ) . History bilateral oophorectomy hysterectomy . Women pregnant , breastfeeding , plan become pregnant study become pregnant study . History active presence myocardial infarction ischemic disease . History active presence cerebrovascular accident , stroke , transient ischemic attack . History presence thrombosis , thromboembolic disease coagulopathy include , limited , pulmonary embolism , deep venous thrombosis , phlebitis intravascular clot disorder . History known presence acquire inherited thrombophilia , include , limited , antithrombin deficiency , Protein C and/or S deficiency , antiphospholipid deficiency , Factor V Leiden mutation prothrombin mutation . Thalassemia sickle cell disease ( sickle cell trait individual exclude ) . History presence subarachnoid hemorrhage . Use anticipated use medication take relieve βHydroxy βmethylbutyric acid ( HMB ) include use vaginal [ ring , cream , gel ] transdermal hormone product ; use oral estrogen , progestin SERMcontaining drug product , intrauterine progestin contain drug product . Use anticipated use Lupron ( 1 3 month ) depot injection estrogen pellet longacting progestin injectables . Use anticipated use meclofenamate sodium , mefenamic acid , danazol , desmopressin acetate herbal remedy . Herbal remedy include , limited , Capsella bursa pastoris ( i.e . Sheperd 's Purse ) , Agnus castus ( i.e . Chasteberry , Vitex ) , Cimicifuga racemosa ( i.e . Black Cohosh ) , Symphytum officionale ( i.e . Comfrey ) , and/or Angelica sinensis ( i.e . Dong Quai ) . Use anticipated use follow drug : oral , transdermal , injectable vaginal ring ( NuvaRing® ) hormonal contraceptive ; anticoagulant ( warfarin [ Coumadin® ] , heparin , lowmolecularweight heparin ( LMWH ) , etc . ) , aminocaproic acid ( Amicar® ) Plaquenil® . Current use intrauterine device ( IUD ) copper IUDs . History presence hypersensitivity idiosyncratic reaction antifibrinolytics ( tranexamic acid aminocaproic acid ) . Use investigational drug except XP12BMR current study . Presence untreated malabsorption disorder malnutrition include , limited , chronic diarrhea , celiac disease , short bowl syndrome , Whipple 's disease history gastric bypass procedure . Presence defective color vision determine optometrist ophthalmologist . Inability subject correctly identify symbol plate 7 HRR eye test consider defective color vision provide subject correctly identify symbol plate 1120 . History presence glaucoma , ocular hypertension , macular degeneration retinopathy . History presence alcoholism drug abuse within past year . Malignancy , treatment malignancy , within previous 2 year , exception basal cell carcinoma skin squamous cell carcinoma skin . Does read understand English .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Menorrhagia</keyword>
	<keyword>Heavy Menstrual Bleeding</keyword>
	<keyword>Lysteda</keyword>
</DOC>